Sean Beinart, MD
Clinical Cardiac Electrophysiology · Rockville, MDNPI 1083714661
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $248,439 of the $315,212 with a category attached, or 78.8%. 36 manufacturers reported payments, led by Johnson & Johnson at 26.6% of the total. Reporting peaked in 2019 at $112,838 and has fallen 96.9% since, to $3,470 in 2025. Among clinical cardiac electrophysiology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 708 payments — averaging $445.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$84K
- Lundbeck LLC$61K
- Sanofi-aventis U.S. LLC$56K
- Abbott$37K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$33K
- E.r. Squibb & Sons, L.L.C.$15K
- plus $29K from 30 others
Across 77 payments — averaging $4434.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$256K
- Medtronic$48K
- Abbott$38K
What the payments were for
- Consulting fees$31,57410%
- Speaking & faculty fees$248,43979%
- Travel & lodging$19,9156%
- Food & beverage$15,1975%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 114 | $83,733 |
| Lundbeck LLC | 63 | $61,028 |
| Sanofi-aventis U.S. LLC | 37 | $56,154 |
| Abbott | 140 | $37,097 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 75 | $33,078 |
| E.r. Squibb & Sons, L.L.C. | 53 | $14,977 |
| Pfizer | 27 | $11,012 |
| Philips North America LLC | 10 | $7,133 |
| Medtronic(3 entities) | 61 | $7,045 |
| AOP Health US, LLC | 1 | $695 |
| Novartis | 24 | $499 |
| Boehringer Ingelheim | 22 | $453 |
| Amgen | 12 | $321 |
| Boston Scientific | 9 | $281 |
| Atricure, Inc. | 8 | $238 |
| Kestra Medical Technology Services, Inc. | 6 | $200 |
| Amarin Pharma, Inc. | 4 | $171 |
| AstraZeneca | 6 | $169 |
| Sanofi | 1 | $160 |
| Esperion Therapeutics, Inc. | 2 | $138 |
| Merck | 6 | $100 |
| Novo Nordisk | 3 | $74 |
| Cardiva Medical, Inc. | 3 | $70 |
| Scpharmaceuticals Inc. | 3 | $47 |
| Irhythm Technologies, Inc. | 2 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Biotronik Inc. | 2 | $44 |
| Medicomp Inc | 2 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| Teleflex LLC | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| Corcept Therapeutics | 1 | $23 |
| Abiomed | 1 | $15 |
| Acutus Medical, Inc. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Edwards Lifesciences | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$82,290
- NORTHERA$60,204
- MULTAQ$41,115
- LifeVest$31,894
- ELIQUIS$24,921
- CVX-300$6,800
- Ensite Cardiac Mapping System$6,325
- ADVISOR$6,050
- ENSITE$5,642
- EnSite Precision Cardiac Mapping System$4,950
- ViewMate Intracardiac Echo$4,125
- AVEIR$3,225
- Reveal LINQ$2,527
- ENSITE PRECISION$2,497
- Accent Pacemaker$1,500
- Rapiblyk$1,389
- EVERA MRI XT DR SURESCAN$919
- SelectSecure$414
- Confirm Rx$386
- AZURE XT DR MRI SURESCAN$356
How this compares
$315,212 in reported general payments places this provider in the 95th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
See all clinical cardiac electrophysiology providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 314 | $397,148 |
| EntrestoSacubitril/Valsartan | 72 | $103,808 |
| XareltoRivaroxaban | 79 | $101,704 |
| MultaqDronedarone Hcl | 19 | $31,005 |
| JardianceEmpagliflozin | 24 | $23,689 |
| Repatha SureclickEvolocumab | 20 | $10,966 |
| FarxigaDapagliflozin Propanediol | 11 | $7,545 |
| Metoprolol Succinate | 332 | $6,844 |
| Dofetilide | 17 | $3,025 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $3,001 |
| Atorvastatin Calcium | 165 | $2,346 |
| Nebivolol Hcl | 16 | $2,104 |
| Amiodarone Hcl | 36 | $1,949 |
| Flecainide Acetate | 57 | $1,693 |
| Losartan Potassium | 122 | $1,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11,012 | $397,148314 claims |
| NovartisEntresto | $499 | $103,80872 claims |
| Johnson & JohnsonXarelto | $83,733 | $101,70479 claims |
| Sanofi-aventis U.S. LLCMultaq | $56,154 | $31,00519 claims |
| Boehringer IngelheimJardiance | $453 | $23,68924 claims |
| AstraZenecaFarxiga | $169 | $7,54511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
Other clinical cardiac electrophysiology in Rockville
- Helen BaroldRockville$83K
- Alexander AsserRockville$20K
- Tushina JainRockville$11K
- Charles LoveBaltimore$238K
- Hugh CalkinsBaltimore$202K
- Paresh ShahBaltimore$97K
- Jonathan ChrispinBaltimore$77K
- Sung LeeTakoma Park$68K
- Stephen ShorofskyBaltimore$63K
- Nilofar IslamTowson$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.